BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019;19:447. [PMID: 31113384 DOI: 10.1186/s12879-019-4085-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Saha K, Sarkar D, Khan U, Karmakar BC, Paul S, Mukhopadhyay AK, Dutta S, Bhattacharya S. Capsaicin Inhibits Inflammation and Gastric Damage during H pylori Infection by Targeting NF-kB–miRNA Axis. Pathogens 2022;11:641. [DOI: 10.3390/pathogens11060641] [Reference Citation Analysis]
2 Hiengrach P, Panpetch W, Chindamporn A, Leelahavanichkul A. Helicobacter pylori, Protected from Antibiotics and Stresses Inside Candida albicans Vacuoles, Cause Gastritis in Mice. IJMS 2022;23:8568. [DOI: 10.3390/ijms23158568] [Reference Citation Analysis]
3 Gebeyehu E, Nigatu D, Engidawork E. Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study. PLoS One 2019;14:e0225585. [PMID: 31756217 DOI: 10.1371/journal.pone.0225585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Mcnicholl AG, Gisbert JP. Reply. Clin Gastroenterol Hepatol 2019;17:2822-3. [PMID: 31757363 DOI: 10.1016/j.cgh.2019.05.054] [Reference Citation Analysis]
5 O'connor A, Furuta T, Gisbert JP, O'morain C. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25. [DOI: 10.1111/hel.12743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Reference Citation Analysis]
7 Jaka H, Rüttgerodt N, Bohne W, Mueller A, Gross U, Kasang C, Mshana SE. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania. Can J Gastroenterol Hepatol 2019;2019:8481375. [PMID: 31355162 DOI: 10.1155/2019/8481375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Gebeyehu E, Nigatu D, Engidawork E. Complete symptom resolution as predictor of Helicobacter pylori eradication and factors affecting symptom resolution: Prospective follow up study. PLoS One 2021;16:e0246624. [PMID: 33571257 DOI: 10.1371/journal.pone.0246624] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, Gartner F, Touati E, Gomes J, Costa P, Martins MCL, Gonçalves IC. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater 2020;114:206-20. [PMID: 32622054 DOI: 10.1016/j.actbio.2020.06.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
10 Nakase K, Nakanishi-Yamasaki M, Harada K, Koizumi J, Yamada T, Ikoshi H, Nakaminami H, Noguchi N. Antimicrobial activity and additive effect of the modified Gingyo-san with antimicrobials against Helicobacter pylori. J Infect Chemother 2021;27:957-61. [PMID: 33602640 DOI: 10.1016/j.jiac.2021.02.008] [Reference Citation Analysis]